NCT06784648

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Public trial-level signal summary for this oncology Phase 2 record.

Record overview

Status and phase

Status: ACTIVE_NOT_RECRUITING

Phase: PHASE1, PHASE2

Sponsor: BioInvent International AB

Condition: Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent, Melanoma Stage III or IV, Melanoma, Melanoma Negative for bRAF, Melanoma Negative for nRAS, Melanomas, Uveal Melanoma, Metastatic

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: primary_completion_date_past_signal | completion_date_past_signal | long_recruitment_duration_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.